Table 1.
Participant Baseline Characteristics
| Characteristic | Total (N = 60) | Study Arm | |
|---|---|---|---|
| Ruxolitinib (n = 40) | Controls (n = 20) | ||
| Age, y, median (IQR) | 49.0 (36.5–54.0) | 49 (45–54) | 43.5 (31.0–54.0) |
| Sex | |||
| Male | 48 (80) | 32 (80) | 16 (80) |
| Female | 12 (20) | 8 (20) | 4 (20) |
| Race/ethnicity | |||
| White non-Hispanic | 21 (36) | 14 (37) | 7 (35) |
| Black non-Hispanic | 29 (50) | 19 (50) | 10 (50) |
| Hispanic (any race) | 6 (10) | 4 (11) | 2 (10) |
| >1 race | 2 (3) | 1 (3) | 1 (5) |
| IV drug history | |||
| Never | 52 (87) | 33 (83) | 19 (95) |
| Previously | 8 (13) | 7 (18) | 1 (5) |
| Entry CD4 count, cells/μL, median (IQR) | 791 (622–972) | 798 (628–973) | 737 (610–930) |
| Entry CD8 count, cells/μL, median (IQR) | 644 (490–852) | 704 (483–842) | 629 (496–852) |
| Entry CD4/CD8 ratio, median (IQR) | 1.3 (0.9–1.6) | 1.3 (0.9–1.6) | 1.3 (0.8–1.6) |
| Nadir CD4 cell count, cells/μL | |||
| ≤50 | 3 (5) | 3 (8) | 0 (0) |
| 51–100 | 3 (5) | 2 (5) | 1 (5) |
| 101–200 | 10 (18) | 7 (18) | 3 (16) |
| 201–500 | 31 (54) | 21 (55) | 10 (53) |
| >500 | 10 (18) | 5 (13) | 5 (26) |
| HIV-1 RNA, copies/mL | |||
| <40 | 59 (98) | 39 (98) | 20 (100) |
| 114 | 1 (2) | 1 (3) | 0 (0) |
| ART regimen | |||
| TDF/FTC/EFV | 20 (33) | 14 (35) | 6 (30) |
| ABC/3TC/DTG | 13 (22) | 8 (20) | 5 (25) |
| TAF/FTC/RPV | 7 (12) | 3 (8) | 4 (20) |
| TAF/FTC + DTG | 5 (8) | 4 (10) | 1 (5) |
| TDF/FTC + RAL | 5 (8) | 4 (10) | 1 (5) |
| TAF/FTC + RAL | 4 (7) | 2 (5) | 2 (10) |
| TDF/FTC + DTG | 3 (5) | 3 (8) | 0 (0) |
| TDF/FTC/RPV | 2 (3) | 1 (3) | 1 (5) |
| ABC/3TC + DTG | 1 (2) | 1 (3) | 0 (0) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; IV, intravenous; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.